Loading data for ADMA — first visit, this takes a few seconds.

알림

ADMA Biologics Inc. (ADMA)

NasdaqGM: ADMA · 실시간 가격 · USD

10.02

+0.48 (5.03%)

종가 기준: Aug 19, 2026, 2:34 PM

5.03% (1D)

매수호가	n/a
시가총액	2.24B
매출 (ttm)	512.28M
순이익 (ttm)	168.96M
베타	0.77
EPS (ttm)	0.7
P/E (ttm)	14.31
선행 P/E	10.19
P/B (ttm)	5.53
P/S (ttm)	4.38
Earnings Date	Nov 4, 2026

매도호가	n/a
거래량	1,296,620
평균 거래량 (20일)	3,075,372
시가	9.76
전일 종가	9.54
일중 범위	9.70 - 10.12
52주 범위	7.21 - 20.46
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

ADMA 소개

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodef...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Oct 17, 2013

직원 수 640

상장 거래소 NasdaqGM

티커 ADMA

웹사이트 https://www.admabiologics.com

전체 기업 정보

재무 실적

2025년 ADMA Biologics의 매출은 510.17M로, 전년 426.45M 대비 19.63% 증가했습니다. 순이익은 146.93M로, -25.67% 감소했습니다.

재무제표

어닝 서프라이즈

ADMA Biologics가 Aug 5, 2026에 분기 실적을 발표했습니다:

매출 $124.39M 예상치 하회 $0, 및 1.98% 전년 대비 성장.

EPS 0.17 예상치 상회 0.01, 및 21.43% 전년 대비 성장.

다음 실적 발표

ADMA Biologics Inc.의 실적 발표 예정일은 Nov 4, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1주 전 · Zacks

ADMA Q2 Earnings Meet, Revenues Miss on Bivigam Weakness

ADMA Biologics matches earnings estimates, misses on revenues and maintains its 2026 outlook as strong Asceniv growth offsets continued pressure on Bivigam.

1주 전 · GuruFocus.com

ADMA Biologics Inc (ADMA) (Q2 2026) Earnings Call Highlights: Ascentiv Surges 24% as Gross ...

ADMA Biologics Inc (ADMA) delivers strong Q2 2026 results with record Ascentiv growth and robust cash generation, despite persistent competitive pressures in the standard IG market.

1주 전 · MarketBeat

ADMA Biologics Q2 Earnings Call Highlights

ADMA Biologics (NASDAQ:ADMA) reported second-quarter revenue growth of 2% as increased sales of its ASCENIV immune globulin product offset pressure on BIVIGAM in the standard immunoglobulin market. Th...

2주 전 · Zacks

Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note

Adma Biologics (ADMA) closed the most recent trading day at $8.46, moving 2.42% from the previous trading session.

3주 전 · Zacks

Wall Street Analysts See Adma Biologics (ADMA) as a Buy: Should You Invest?

Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness o...

2 페이지 중 1

ADMA Biologics Inc. (ADMA)